Iterum Therapeutics (ITRM) AI Stock Analysis

• Market Cap: $13.54M
• Dividend Yield: N/A
• Average Volume (3M): 813.22K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.44
• Revenue Growth: N/A
• EPS Growth: 62.61%
• Country: US
• Employees: 9
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.16
• Shares Outstanding: 52,835,200
• 10 Day Avg. Volume: 1,119,323
• 30 Day Avg. Volume: 813,222
• PEG Ratio: 0.02
• Price to Book (P/B): -8.54
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.30
• Enterprise Value/Market Cap: 2.63
• Enterprise Value/Revenue: 91.32
• Enterprise Value/Gross Profit: -53.31
• Enterprise Value/Ebitda: -1.54
• 1Y Price Target: $5.50
• Price Target Upside: 1517.65% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 43 Neutral
• Price Target: $0.31 ▼(-8.53% Downside)

The score is held down primarily by weak financial fundamentals (minimal revenue, persistent losses, cash burn, and negative equity) and bearish technicals (price below major moving averages with negative MACD). The earnings call adds some support due to early launch traction and 2026 revenue guidance, but this is tempered by the need for additional capital, while the Nasdaq listing compliance issue adds further downside risk.

Positive Factors

Patent expansion (China & Mexico)

Extended patents in China and Mexico through 2039–2041 materially lengthen market exclusivity in key international jurisdictions. This strengthens long-term commercial upside, supports pricing power versus generics, and enhances licensing or partnering optionality across global markets.

Initial prescriber adoption of Orlynda

More than 280 prescriptions across 100 unique prescribers at launch indicates early clinical acceptance and real prescriber engagement. Durable prescriber adoption is critical for sustained uptake, repeat prescribing, and revenue scale as payer coverage and distribution expand.

Managed-care rebate agreement

A rebate deal with a top Medicare Part D PBM materially improves payer access and formulary placement prospects beginning 2026/2027. Structural gains in coverage can raise fill rates, reduce out-of-pocket barriers, and support steadier prescription growth over multiple years.

Negative Factors

Negative shareholders' equity and elevated leverage

Negative equity and debt that exceeds assets constrain financial flexibility and increase refinancing and dilution risk. This capital-structure weakness can limit investment in commercial scale-up or R&D and raises vulnerability to adverse funding conditions over the next several quarters.

Ongoing cash burn and capital needs

Sustained operating cash burn (~-$19.9M TTM) and management's plan to seek additional funding create execution risk. Reliance on new capital can dilute shareholders and, if market access tightens, could slow commercialization and delay achieving self-sustaining cash generation.

Nasdaq listing compliance / delisting risk

Active non-compliance notices on market value and minimum bid price create a persistent governance and liquidity risk. A delisting or prolonged compliance process would impair access to U.S. capital markets, raise financing costs, and hamper long-term commercialization and investor confidence.

Iterum Therapeutics Business Overview & Revenue Model

Company Description

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.

How the Company Makes Money

Iterum Therapeutics makes money through the development and potential commercialization of its primary product candidate, sulopenem. The company's revenue model is expected to include income from the sale of sulopenem upon receiving regulatory approval, which would allow the company to market the drug to healthcare providers and institutions. Additionally, Iterum may pursue licensing agreements, strategic partnerships, and collaborations with other pharmaceutical companies to enhance distribution and commercialization efforts. These partnerships could provide upfront payments, milestone payments, and royalties based on sales, contributing significantly to the company's earnings. As a clinical-stage company, Iterum may also rely on funding from investors, grants, and other financial instruments to support its research and development activities until its products reach the market.

Iterum Therapeutics Financial Statement Overview

Summary

Very limited TTM revenue ($0.39M) with continued large losses (net loss ~$27.0M) and ongoing cash burn (operating/free cash flow about -$19.9M TTM). While losses, cash burn, and debt have improved versus prior years, negative shareholders’ equity (about -$7.4M TTM) and debt exceeding assets keep financial risk high.

Income Statement

TTM (Trailing-Twelve-Months) results show minimal revenue ($0.39M) and deeply negative profitability (net loss of about $27.0M), with gross profit also negative. Losses have narrowed versus prior years (net loss ~$91.6M in 2021 to ~$24.8M in 2024 and ~$27.0M TTM), but the business is still far from operating break-even and margins remain structurally weak.

Balance Sheet

Leverage is elevated relative to the company’s asset base (TTM debt ~$33.7M vs. assets ~$32.5M), and shareholders’ equity is negative (TTM about -$7.4M; also negative in 2023–2024), which limits financial flexibility and raises refinancing/dilution risk. A positive is that total debt has come down from 2024 (~$45.5M) to TTM (~$33.7M), but the capital structure remains pressured given negative equity.

Cash Flow

Cash burn remains significant with operating cash flow around -$19.9M TTM and free cash flow around -$19.9M, indicating the business is still consuming cash to fund operations. The burn rate has improved versus 2023–2024 (operating cash flow -$39.3M in 2023 and -$26.8M in 2024), and TTM free cash flow shows strong improvement versus the prior period (growth ~35%), but cash generation is not yet self-sustaining.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	390.00K	0.00	0.00	0.00	0.00	0.00
Gross Profit	-668.00K	-254.00K	-1.75M	-1.80M	-2.10M	-161.00K
EBITDA	-23.07M	-21.73M	-34.58M	-39.97M	-83.20M	-36.01M
Net Income	-26.96M	-24.77M	-38.37M	-44.43M	-91.56M	-52.01M
Balance Sheet
Total Assets	32.50M	44.59M	26.26M	66.83M	91.51M	32.79M
Cash, Cash Equivalents and Short-Term Investments	11.00M	24.13M	23.93M	60.80M	81.34M	14.57M
Total Debt	33.73M	45.53M	18.96M	30.10M	30.43M	48.08M
Total Liabilities	39.88M	48.68M	32.66M	38.83M	41.27M	83.35M
Stockholders Equity	-7.38M	-4.08M	-6.40M	28.00M	50.23M	-50.56M
Cash Flow
Free Cash Flow	-19.93M	-26.77M	-39.34M	-18.54M	-15.90M	-54.54M
Operating Cash Flow	-19.91M	-26.77M	-39.33M	-18.47M	-15.84M	-54.53M
Investing Cash Flow	1.09M	18.21M	23.34M	13.96M	-54.59M	-11.00K
Financing Cash Flow	16.27M	26.69M	1.03M	-1.82M	83.13M	64.47M

Iterum Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.34
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ITRM, the sentiment is Negative. The current price of 0.34 is above the 20-day moving average (MA) of 0.31, below the 50-day MA of 0.34, and below the 200-day MA of 0.67, indicating a bearish trend. The MACD of -0.02 indicates Positive momentum. The RSI at 31.17 is Neutral, neither overbought nor oversold. The STOCH value of 10.37 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ITRM.

Iterum Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
XLO	49 Neutral	$40.91M	―	-908.28%	―	588.40%	61.76%
CAMP	49 Neutral	$210.64M	-1.63	-172.70%	―	―	5.51%
RADX	47 Neutral	$55.08M	-1.41	-98.81%	―	―	―
CLNN	45 Neutral	$49.70M	-1.33	―	―	-49.17%	23.37%
ITRM	43 Neutral	$13.54M	-0.32	―	―	―	62.61%
CVM	43 Neutral	$40.19M	-1.01	-176.32%	―	―	48.68%

Iterum Therapeutics Corporate Events

Iterum Therapeutics Faces Nasdaq Listing Compliance Challenge

On December 11, 2025, Iterum Therapeutics received a notification from Nasdaq indicating that it no longer meets the listing requirements due to its market value of listed securities falling below $35 million for 30 consecutive business days. The company has until June 9, 2026, to regain compliance, or it risks delisting. Additionally, Iterum was previously notified on August 25, 2025, about non-compliance with the minimum bid price rule, with a deadline of February 23, 2026, to address this issue. Failure to meet these requirements could lead to delisting, although the company may appeal any delisting decisions.

The most recent analyst rating on (ITRM) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on Iterum Therapeutics stock, see the ITRM Stock Forecast page.